Luke Timmerman

Seattle biotech gets OK for drug

ZymoGenetics won U.S. approval to market its first product, a drug to stop excess bleeding in as many as 1 million surgeries a year. The...

Provenge critics receive threats

Two cancer doctors have received threatening e-mails in recent weeks because of their opposition to Provenge, an experimental prostate-cancer...